Business Context and Reporting Period
This Form 8-K Current Report from Silexion Therapeutics Corp (SLXN) covers events occurring on May 5, 2026. The filing documents the reconvening of an extraordinary general meeting originally held on April 28, 2026, which was adjourned due to a lack of quorum. The meeting was successfully reconvened to vote on corporate governance and capital structure proposals.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements, revenue, profit, cash flow, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
Shareholders approved three significant proposals at the reconvened meeting:
- Authorized Share Capital Increase: The company increased its authorized share capital from 9,000,000 ordinary shares to 59,000,000 ordinary shares. The total authorized capital increased from US$121,500 to US$796,500.
- Equity Incentive Plan Amendment: The "evergreen" provision of the 2024 Equity Incentive Plan was amended. The annual share addition will now be calculated to maintain a total pool of shares reserved under all equity incentive plans at 10% of issued and outstanding ordinary shares on a fully diluted basis, replacing the previous 5% of issued and outstanding shares metric.
- Reverse Share Split Authorization: The Board of Directors was authorized to effect a 1-for-10 reverse share split. This will consolidate issued and outstanding shares and adjust the par value from $0.0135 to $0.135 per share. The ratio may be reduced if necessary to comply with Nasdaq listing rules regarding publicly held shares.
Voting Results and Quorum
At the reconvened meeting, 1,638,079 ordinary shares (approximately 40.2% of issued and outstanding shares) were present. Under the company's Articles, these shareholders constituted a quorum after a 30-minute lapse. All three proposals were approved by a simple majority of votes cast:
- Proposal 1 (Capital Increase): 61.4% in favor, 38.6% against.
- Proposal 2 (Equity Plan): 61.4% in favor, 38.6% against.
- Proposal 3 (Reverse Split): 61.3% in favor, 38.7% against.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard implications of the approved corporate actions. The reverse share split is explicitly noted as subject to reduction to maintain compliance with Nasdaq listing rules.
Investor Verification Checklist
- Verify the effective date and implementation timeline for the 1-for-10 reverse share split.
- Confirm the updated total number of authorized shares (59,000,000) in subsequent filings.
- Review the impact of the new 10% fully diluted equity incentive pool on future dilution.
- Monitor Nasdaq compliance status regarding the reverse split and minimum bid price requirements.